

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

POSITIVE PROFIT ALERT
ANNOUNCEMENT FOR THE ESTIMATED
2024 INTERIM RESULTS

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) pursuant to the requirements of Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) for the purpose of providing shareholders of the Company (the “**Shareholders**”) and the public with the financial information of the Company. This announcement is also published in accordance with Rule 13.10B of the Listing Rules as it is also published on the Shenzhen Stock Exchange.

The following is the estimated interim results for the six months ended June 30, 2024 (“**Reporting Period**”) of the Company together with its subsidiaries (the “**Group**”). The financial data contained in this results estimate has not been audited and is, except for non-IFRSs (International Financial Reporting Standards) adjusted net profit attributable to shareholders of the listed company or as otherwise indicated, prepared in accordance with the People’s Republic of China Accounting Standards for Business Enterprises. Detailed financial information of the Group for the Reporting Period will be disclosed in the interim results announcement of the Company for the Reporting Period, which is expected to be published on or before August 31, 2024 in accordance with the Listing Rules.

I. ESTIMATED RESULTS FOR THE PERIOD

- (1) Period to which the estimated results apply
From January 1, 2024 to June 30, 2024
- (2) Expected results
 Loss Turnaround Increase compared with the corresponding period
 Decrease compared with the corresponding period

Items	During the Reporting Period	Corresponding period of last year
Net profit attributable to shareholders of the listed company	Earnings: RMB642.28 million to RMB734.82 million	Earnings: RMB123.35 million
	Increase as compared with the corresponding period: 420.70% to 495.72%	
Net profit after non-recurring profit or loss	Earnings: RMB308.07 million to RMB400.61 million	Earnings: RMB79.61 million
	Increase as compared with the corresponding period: 286.96% to 403.20%	
Basic earnings per share	Earnings: RMB0.4377 per share to RMB0.5008 per share	Earnings: RMB0.0841 per share

II. COMMUNICATION WITH THE ACCOUNTING FIRM

The relevant data of this results estimate have not been audited by an accounting firm.

III. REASONS FOR CHANGES IN THE RESULTS

1. During the Reporting Period, the operating environment of the heparin industry chain improved, and there were signs of recovery in market demand. The Company actively implemented its brand's international expansion strategy, leveraging the advantages of its marketing networks both domestically and overseas. The development of the heparin finished dose business has been promising, with continued growth in sales of the main product, finished dose enoxaparin sodium pharmaceutical products, in markets such as Europe, the United States, and China, further increasing the Company's global market share. At the same time, due to the combined effects of a well-maintained pricing system, improved cost control efficiency, and reduced raw material costs, the gross profit margin of the finished dose products has increased compared to the same period last year, after excluding the impact of centralized procurement prices in the Chinese market.

2. During the Reporting Period, global demand for heparin APIs recovered. The export volume of Chinese heparin APIs showed a significant increase compared to the same period last year. However, factors such as a substantial decrease in upstream raw material prices resulted in a significant decline in export unit prices compared to the previous year. The Company adhered to a strategy of focusing on established and regulated markets, prioritizing product competitiveness, and actively maintained the API pricing system, yielding positive results. The average selling price of the products during the Reporting Period was significantly higher than the overall export average price in China, with sales volume also achieved significant growth. Coupled with factors such as a significant reduction in costs, the Company's API business performed well overall.
3. The Company's CDMO business continued its recovery momentum. During the Reporting Period, the Company consistently strengthened and deepened strategic partnerships with existing clients while actively exploring new customer bases. Internal resources were integrated to build diversified commercial capabilities, aiming to enhance the profitability of the CDMO business.
4. The Company has continued to optimize its external investment strategy and further optimized its investment portfolio with the premise of maximizing shareholders' interests, and has achieved greater progress and breakthroughs. During the Reporting Period, the Company partially disposed of its equity interest in an associate, HighTide Therapeutics, Inc. ("**HighTide**"). Additionally, in order to support the better self-determined development of HighTide, the Company resigned from the directorship position it had appointed to HighTide during the Reporting Period. As of the end of the Reporting Period, the Company no longer had joint control or significant influence over HighTide, and the Company will change the accounting treatment of its equity interest in HighTide in accordance with relevant regulations. The partial disposal of equity interest in HighTide and the change in accounting treatment are expected to bring investment income of over RMB250 million to the Company during the Reporting Period. The related investment income will be accounted for as non-recurring gains or losses.

IV. OTHER RELEVANT INFORMATION

The Company is still in the course of finalizing its consolidated financial results of the Group for the Reporting Period. The information contained in this announcement is only based on the preliminary assessment made by the Board of Directors of the Company (the “**Board**”) by reference to the Group’s unaudited consolidated management accounts and the information currently available to the Board. Such information has neither been confirmed nor audited by the accounting firm of the Company or the audit committee of the Board and may be subject to change. Shareholders and potential investors are advised to refer to the Company’s announcement relating to the interim results of the Group for the Reporting Period, which is expected to be published on or before August 31, 2024. **Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
July 12, 2024

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Pang and Mr. Yi Ming.